<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03028701</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-20.13</org_study_id>
    <nct_id>NCT03028701</nct_id>
  </id_info>
  <brief_title>Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD</brief_title>
  <acronym>COPD</acronym>
  <official_title>Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to asses the bronchodilator effect of single dose of&#xD;
      Formoterol/Budesonide 12/400 mcg fixed combination delivered via Discair® in patients with&#xD;
      COPD.&#xD;
&#xD;
      Spirometric measurements (FEV1, FVC) will be performed for a period of 12 h at 12 different&#xD;
      times: pretreatment (prior to the first dose) and posttreatment (15. min, 30. min, 1 hr, 2&#xD;
      hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr ve 12 hr).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective is to asses the bronchodilator effect of single dose of&#xD;
      Formoterol/Budesonide 12/400 mcg fixed dose combination delivered via Discair® in patients&#xD;
      with COPD.&#xD;
&#xD;
      Patients will be assigned to receive single dose of Formoterol/Budesonide 12/400 mcg fixed&#xD;
      dose combination delivered via Discair® (test product, n = 33). Patients will be evaluated at&#xD;
      4 consecutive visits: baseline (enrollment), screening, treatment, and end of treatment (24h&#xD;
      after treatment).&#xD;
&#xD;
      For newly diagnosed and formerly diagnosed patients who are not on COPD medication, the&#xD;
      screening visit will be performed on the day of enrollment. For formerly diagnosed patients&#xD;
      receiving COPD treatment, the day of the screening visit will be based on the completion of a&#xD;
      run-in period, with the length determined by the specific medication. During the run-in&#xD;
      period, salbutamol (100 μg inhaler) will be prescribed as a rescue medication.&#xD;
&#xD;
      Spirometric measurements (FEV1, FVC) will be performed for a period of 12 h at 12 different&#xD;
      times: pretreatment (prior to the first dose) and posttreatment (15. min, 30. min, 1 hr, 2&#xD;
      hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr ve 12 hr).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean max improvement (ml) from baseline in FEV1 over a period of 12 h.</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time to onset of max improvement from baseline in FEV1.</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change (ml) from baseline in FEV1 over a period of 12 h (over spirometric measurement period).</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean absolute change (ml) from baseline in FVC over a period of 12 h (over spirometric measurement period).</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean % change from baseline in FEV1 over a period of 12 h (over spirometric measurement period).</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean % change from baseline in FVC over a period of 12 h (over spirometric measurement period).</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (AUC0-12) response</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (AUC0-12) response</measure>
    <time_frame>Pretreatment (prior to the first dose of study medication) and posttreatment (Day 1)</time_frame>
    <description>Spirometric measurements will be made at prior to the first dose of study medication and and posttreatment at 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 10 hr and 12 hr.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety</measure>
    <time_frame>Predose and up to 12 hours postdose</time_frame>
    <description>(Physical examination, numbers of adverse reactions and abnormal laboratory values related</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Copd</condition>
  <arm_group>
    <arm_group_label>Formoterol/Budesonide 12/400 mcg Discair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol/Budesonide 12/400 mcg Discair</intervention_name>
    <description>Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®</description>
    <arm_group_label>Formoterol/Budesonide 12/400 mcg Discair</arm_group_label>
    <other_name>Forpack Discair® Inhalation Powder 12/400 mcg.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥40 years with newly or formerly diagnosed moderate to severe COPD&#xD;
             (Patients with postbronchodilator FEV1/FVC ratio &lt;0.70, and FEV1 &lt;80% of predicted&#xD;
             normal. Patients have chronic cough or chronic productive cough with breathlessness&#xD;
             even walking slowly along flat ground.) Current smokers or exsmokers with a smoking&#xD;
             history of at least 10 pack-years&#xD;
&#xD;
          -  Patients who have no exacerbation within last 4 weeks&#xD;
&#xD;
          -  Females patients with childbearing potential using effective birth control method&#xD;
&#xD;
          -  Patients who has a capability of communicate with investigator&#xD;
&#xD;
          -  Patients who accept to comply with the requirements of the protocol&#xD;
&#xD;
          -  Patients who signed written informed consent prior to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have history of hypersensitivity to drugs contains long-acting&#xD;
             beta2-agonist or corticosteroids&#xD;
&#xD;
          -  Patients who have abnormal blood glucose level ((≥140 mg/dl)&#xD;
&#xD;
          -  Patients who have unregulated diabetes mellitus&#xD;
&#xD;
          -  Patients who have a serum potassium level of ≤3.5 mEq/L or &gt;5.5mEq/L&#xD;
&#xD;
          -  Patients who have asthma&#xD;
&#xD;
          -  Patients who have a history of myocardial infarction, severe hearth failure, acute&#xD;
             ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least&#xD;
             6 weeks&#xD;
&#xD;
          -  Patients who have lung cancer&#xD;
&#xD;
          -  Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening&#xD;
             visit or during run-in period.&#xD;
&#xD;
          -  Patients who had COPD exacerbation or lower respiratory track infections that required&#xD;
             antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to&#xD;
             screening visit or during run-in period.&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  History of allergic rhinitis or atopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pınar Yıldız, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital Istanbul, Turkey, 34020</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Yildiz P, Bayraktaroglu M, Gorgun D, Yuksel K. Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair(®) in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. Clin Drug Investig. 2019 Oct;39(10):991-1001. doi: 10.1007/s40261-019-00828-y.</citation>
    <PMID>31332649</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Formoterol</keyword>
  <keyword>Budesonide</keyword>
  <keyword>Dry powder inhalation</keyword>
  <keyword>Discair</keyword>
  <keyword>COPD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

